Phase 3 Study Comparing MRTX849 and Cetuximab to Chemotherapy for Advanced Colorectal Cancer with KRAS G12C Mutation
Sponsor: Mirati Therapeutics Inc.
Sponsor score: 40
ClinicalTrials ID:NCT04793958
This clinical trial is testing a new treatment combination of MRTX849 and cetuximab against standard chemotherapy for patients with advanced colorectal cancer that has a specific genetic mutation called KRAS G12C.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to compare the effectiveness of a new treatment combination, MRTX849 and cetuximab, with standard chemotherapy in patients who have advanced colorectal cancer with a KRAS G12C mutation. This trial is for patients who have already received one type of chemotherapy and whose cancer has continued to grow.
Eligibility Criteria
Inclusion Criteria
- Have a confirmed diagnosis of colorectal cancer with a KRAS G12C mutation.
- Have previously received first-line treatment for advanced colorectal cancer with a chemotherapy regimen that included either oxaliplatin or irinotecan.
- Have evidence that the cancer has progressed after the first-line treatment.
Exclusion Criteria
- Have previously received treatment targeting the KRAS G12C mutation.
- Have previously been treated with anti-EGFR antibodies like cetuximab or panitumumab.
- Have active cancer that has spread to the brain.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Local Institution - 010-855-E | 35007 | Alabaster | Alabama |
| Local Institution - 010-855-B | 35022 | Bessemer | Alabama |
| Local Institution - 010-855-D | 35209 | Birmingham | Alabama |
| Local Institution - 010-855-A | 35211 | Birmingham | Alabama |
| Local Institution - 010-855-F | 35235 | Birmingham | Alabama |
| Local Institution - 010-855-C | 35243 | Birmingham | Alabama |
| Local Institution - 010-855 | 35243 | Birmingham | Alabama |
| Local Institution - 010-996 | 85234 | Gilbert | Arizona |
| Local Institution - 010-566 | 85338 | Goodyear | Arizona |
| Local Institution - 010-989 | 85054 | Phoenix | Arizona |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.